The primary obstacle to leveraging AI in bioprocessing isn't developing advanced models, but solving the pre-existing, complex challenge of data readiness. Companies are still struggling to unify disparate data from different tools, sites, and GMP vs. development environments, turning intended "data lakes" into inaccessible "data swamps."

Advanced AI models are ineffective in clinical settings without a robust data layer. Ambience had to solve fundamental problems like pulling messy context from inconsistent EHRs and preserving 'decision traces,' which are often destroyed by existing systems with mutable data structures.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

The bottleneck for AI in drug discovery is not the algorithm but the lack of high-quality, large-scale biological data. New platforms are needed to generate this necessary "substrate" for AI models to learn from, challenging the narrative that better models alone are the solution.

The primary bottleneck for creating powerful foundation models in biology is the lack of clean, large-scale experimental data—orders of magnitude less than what's available for LLMs. This creates a major opportunity for "data foundries" that use robotic labs to generate high-quality biological data at scale.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

AI's potential in drug discovery is contingent on having a robust "data factory" to generate massive, high-quality biological datasets. Najat Khan emphasizes that the combination of this data infrastructure, AI, supercomputing, and human expertise is what creates a true competitive advantage, not the algorithm alone.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.